Drug intelligence / Profile preview

[11C]PE2I

Development stage: Phase 2
Lead developer: Weill Cornell Medicine
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration: Intravenous

Overview

[11C]PE2I is a highly selective radioligand used in Positron Emission Tomography (PET) imaging. It binds specifically to the dopamine transporter (DAT) and is used for in vivo visualization of dopamine transporter availability in the brain, primarily for the differential diagnosis of parkinsonian disorders.

Other names: N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-3β-(4-methyl-phenyl)nortropane

Targets

DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on [11C]PE2I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [11C]PE2I.